Results 81 to 90 of about 694 (96)

Novel Therapeutics in Soft Tissue Sarcoma. [PDF]

Cancers (Basel)
Mavroeidis L, Napolitano A, Huang P, Jones RL.   +3 more
europepmc   +1 more source

Transcatheter arterial chemoembolization with tyrosine kinase inhibitor in the 12-year treatment of hepatic metastases from gastrointestinal stromal tumor: a case report. [PDF]

J Gastrointest Oncol
Yu B, Luo J, Wu J, Gu L, Zhang Y.
europepmc   +1 more source

Clinicopathologic and molecular spectrum of gastrointestinal stromal tumor (GIST) with NTRK fusion and marked response to larotrectinib in GIST with NTRK fusion: a case report. [PDF]

Cell Oncol (Dordr)
Shen Y, Peng Q, Wen J, Yang L, Zhu L, Chen Y, Liu Q, Wang L, Yao J, Li A, Wang M, Liu Z.   +11 more
europepmc   +1 more source

Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? [PDF]

Cancers (Basel)
Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N.   +19 more
europepmc   +1 more source

Cu-Catalyzed [1,3]-Fluorine Rearrangement Reactions of <i>N</i>-Fluoroanilines. [PDF]

Org Lett
Nakamura I, Kim J, Suzuki M, Sato T, Terada M.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma

ESMO Open, 2022
Sebastian Bauer, R Ruiz-Soto
exaly  

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor

Clinical Pharmacology in Drug Development, 2022
Rodrigo Ruiz-Soto
exaly  

Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach

Chemico-Biological Interactions, 2023
Qingfeng He, Xiaoqiang Xiang, Xiao Zhu   +2 more
exaly  

Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour

European Journal of Cancer, 2021
Margaret Von Mehren, , Hans Gelderblom
exaly  

Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors

Expert Review of Gastroenterology and Hepatology, 2023
Anastasia Constantinidou, Robin Jones
exaly